Alliancebernstein L.P. Viking Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

A detailed history of Alliancebernstein L.P. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 1,241,125 shares of VKTX stock, worth $76.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,241,125

Previous 1,560,878 20.49%

Holding current value

$76.5 Million

Previous $128 Million 48.6%

% of portfolio

0.02%

Previous 0.05%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $15.2 Million - $25.6 Million	-319,753 Reduced 20.49%	1,241,125 $65.8 Million
Q1 2024 May 14, 2024	SELL	$17.4 - $94.5 $36.8 Million - $200 Million	-2,113,057 Reduced 57.51%	1,560,878 $128 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $1.14 Million - $2.43 Million	123,861 Added 3.49%	3,673,935 $68.4 Million
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $6.43 Million - $9.42 Million	588,513 Added 19.87%	3,550,074 $39.3 Million
Q2 2023 Aug 15, 2023	BUY	$14.84 - $24.79 $43.7 Million - $73.1 Million	2,947,905 Added 21586.88%	2,961,561 $48 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $110,340 - $236,658	13,656 New	13,656 $227,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $167,956 - $250,740	-79,600 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$3.0 - $4.88 $600 - $976	200 Added 0.25%	79,600 $239,000
Q2 2021 Jul 30, 2021	BUY	$5.19 - $6.73 $74,736 - $96,912	14,400 Added 22.15%	79,400 $476,000
Q1 2021 May 06, 2021	SELL	$5.74 - $9.67 $70,028 - $117,974	-12,200 Reduced 15.8%	65,000 $411,000
Q3 2020 Nov 12, 2020	SELL	$5.73 - $8.11 $14,325 - $20,275	-2,500 Reduced 3.14%	77,200 $449,000
Q2 2020 Aug 13, 2020	SELL	$4.35 - $8.08 $16,965 - $31,512	-3,900 Reduced 4.67%	79,700 $575,000
Q1 2020 May 14, 2020	BUY	$3.45 - $7.95 $45,885 - $105,735	13,300 Added 18.92%	83,600 $391,000
Q1 2019 May 14, 2019	BUY	$7.58 - $9.94 $30,320 - $39,760	4,000 Added 6.03%	70,300 $699,000
Q4 2018 Feb 13, 2019	BUY	$7.16 - $16.21 $17,900 - $40,525	2,500 Added 3.92%	66,300 $507,000
Q2 2018 Aug 13, 2018	BUY	$3.88 - $12.74 $247,544 - $812,812	63,800 New	63,800 $605,000

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.73B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Viking Therapeutics, Inc. Transaction History